In 20 years as an executive leader in biotechnology, Andrew Powell has generated more than $20B in shareholder value through a series of successful transactions. Trained as a lawyer, Mr. Powell has been able to motivate diverse teams to see the strategic intersection between risk management (dull) and value creation (exciting). He played a key role developing ImClone, InterMune and Medivation into rigorous commercial organizations that were both compliant and equipped for growth in the U.S. and beyond. Similarly, at CollaGenex Pharmaceuticals and Cornerstone Therapeutics, he helped dynamic leadership navigate change and reinvent IP and regulatory strategies to multiply shareholder value. Mr. Powell’s early experience was in negotiating and managing ex-U.S. joint ventures in developing economies for Baxter International. He continues to maintain an interest in improving the delivery of healthcare services worldwide, and currently serves as an advisor to the WIN and Red Segura non-profit healthcare initiatives, focused on improving maternal health to underserved populations in Senegal and Honduras respectively. Mr. Powell serves on the board of Aclaris, Inc., a NASDAQ listed pharmaceutical company. He has also served as a director of BioLeap, Inc. a start-up computational chemistry company, and as an advisory board member at Vicept Therapeutics, a successful dermatology company. He is a director and Chief Financial Officer of the Robertson Powell Foundation. Mr. Powell attended Winchester College in England, graduated as a Morehead Scholar from the University of North Carolina at Chapel Hill, and earned a Juris Doctor degree at Stanford.